Research programme: high molecular weight GPBP therapeutics- Fibrostatin

Drug Profile

Research programme: high molecular weight GPBP therapeutics- Fibrostatin

Alternative Names: FSM 26; FST 12; GPBP inhibitor; GPBP-Mab; T-12

Latest Information Update: 02 Nov 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator FibroStatin
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Protein serine threonine kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Diabetes mellitus; Idiopathic pulmonary fibrosis; Kidney disorders; Non-small cell lung cancer

Most Recent Events

  • 02 Nov 2016 FibroStatin has patent protection for FST 12 in USA, Europe, Japan and China (FibroStatin website, November 2016)
  • 01 May 2016 Preclinical trials in Breast cancer in Spain (unspecified route)
  • 01 May 2016 Preclinical trials in Diabetes mellitus in Spain (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top